{"DataElement":{"publicId":"2596648","version":"1","preferredName":"Malignant Neoplasm Patient Self-Report Therapy Type","preferredDefinition":"the type of self-reported tumor composed of atypical neoplastic, often pleomorphic cells that invade other tissues.","longName":"MNEO_PSR_TX_TP","context":"NIDCR","contextVersion":"1","DataElementConcept":{"publicId":"2590495","version":"1","preferredName":"Malignant Neoplasm Patient Self-Report Therapy","preferredDefinition":"information related to presence of self-reported tumor composed of atypical neoplastic, often pleomorphic cells that invade other tissues.","longName":"MNEO_PSR_PRES","context":"NIDCR","contextVersion":"1","ObjectClass":{"publicId":"2186369","version":"1","preferredName":"Malignant Neoplasm","preferredDefinition":"A tumor composed of atypical neoplastic, often pleomorphic cells that invade other tissues.  Malignant neoplasms usually metastasize to distant anatomic sites and may recur after excision.  The most common malignant neoplasms are carcinomas (adenocarcinomas or squamous cell carcinomas), Hodgkin's and non-Hodgkin's lymphomas, leukemias, melanomas, and sarcomas. -- 2004","longName":"C9305","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Malignant Neoplasm","conceptCode":"C9305","definition":"A neoplasm composed of atypical neoplastic, often pleomorphic cells that invade other tissues. Malignant neoplasms often metastasize to distant anatomic sites and may recur after excision. The most common malignant neoplasms are carcinomas, Hodgkin and non-Hodgkin lymphomas, leukemias, melanomas, and sarcomas.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"E0647F5B-A888-4B87-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2004-08-03","endDate":null,"createdBy":"REEVESD","dateCreated":"2004-08-03","modifiedBy":"DATA_LOADER","dateModified":"2005-10-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2590493","version":"1","preferredName":"Patient Self-Report Therapy","preferredDefinition":"Subjective reports made by the patient:An action or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process.","longName":"C21089:C15368","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Patient Self-Report","conceptCode":"C21089","definition":"Subjective reports made by a patient.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Therapy","conceptCode":"C15368","definition":"An action or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"27BD5F3D-43C5-0CF3-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-01-23","endDate":null,"createdBy":"ALAIS","dateCreated":"2007-01-23","modifiedBy":"ONEDATA","dateModified":"2007-01-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008551","version":"1","preferredName":"Assessments","preferredDefinition":"evaluations of the patient and the patient's disease.","longName":"ASSESS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22DA727-6718-5A2D-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"27BD6171-1FCF-0D41-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-01-23","endDate":null,"createdBy":"ALAIS","dateCreated":"2007-01-23","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"2596645","version":"1","preferredName":"Malignant Neoplasm Treatment Type","preferredDefinition":"the type of cancer treated.","longName":"MALNEO_TX_TP","context":"NIDCR","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"35","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Prostate Cancer","valueDescription":"Prostate Carcinoma","ValueMeaning":{"publicId":"2596646","version":"1","preferredName":"Prostate Carcinoma","longName":"2596646","preferredDefinition":"Prostate carcinoma is one of the most common malignant tumors afflicting men.  The majority of carcinomas arise in the peripheral zone and a minority occur in the central or the transitional zone of the prostate gland.  Grossly, prostatic carcinomas appear as ill-defined yellow areas of discoloration in the prostate gland lobes.  Adenocarcinomas represent the overwhelming majority of prostatic carcinomas.  Prostatic-specific antigen (PSA) serum test is widely used as a screening test for the early detection of prostatic carcinoma.  Treatment options include radical prostatectomy, radiation therapy, androgen ablation and cryotherapy.  Watchful waiting or surveillance alone is an option for older patients with low-grade or low-stage disease.  -- 2002","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Prostate Carcinoma","conceptCode":"C4863","definition":"One of the most common malignant tumors afflicting men.  The majority of carcinomas arise in the peripheral zone and a minority occur in the central or the transitional zone of the prostate gland.  Grossly, prostatic carcinomas appear as ill-defined yellow areas of discoloration in the prostate gland lobes.  Adenocarcinomas represent the overwhelming majority of prostatic carcinomas.  Prostatic-specific antigen (PSA) serum test is widely used as a screening test for the early detection of prostatic carcinoma.  Treatment options include radical prostatectomy, radiation therapy, androgen ablation and cryotherapy.  Watchful waiting or surveillance alone is an option for older patients with low-grade or low-stage disease.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2962D840-ED32-4EC3-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-02-13","endDate":null,"createdBy":"ALAIS","dateCreated":"2007-02-13","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"2962D840-ED4A-4EC3-E044-0003BA3F9857","beginDate":"2007-02-13","endDate":null,"createdBy":"ALAIS","dateCreated":"2007-02-13","modifiedBy":"ALAIS","dateModified":"2007-02-13","deletedIndicator":"No"},{"value":"Breast Cancer","valueDescription":"Breast Carcinoma","ValueMeaning":{"publicId":"2581276","version":"1","preferredName":"Breast Carcinoma","longName":"2581276","preferredDefinition":"A carcinoma arising from the breast, most commonly the terminal ductal-lobular unit. It is the most common malignant tumor in females. Risk factors include country of birth, family history, menstrual and reproductive history, fibrocystic disease and epithelial hyperplasia, exogenous estrogens, contraceptive agents, and ionizing radiation. The vast majority of breast carcinomas are adenocarcinomas (ductal or lobular). Breast carcinoma spreads by direct invasion, by the lymphatic route, and by the blood vessel route. The most common site of lymph node involvement is the axilla.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Breast Carcinoma","conceptCode":"C4872","definition":"A carcinoma arising from the breast, most commonly the terminal ductal-lobular unit. It is the most common malignant tumor in females. Risk factors include country of birth, family history, menstrual and reproductive history, fibrocystic disease and epithelial hyperplasia, exogenous estrogens, contraceptive agents, and ionizing radiation. The vast majority of breast carcinomas are adenocarcinomas (ductal or lobular). Breast carcinoma spreads by direct invasion, by the lymphatic route, and by the blood vessel route. The most common site of lymph node involvement is the axilla.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-0A89-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-10-18","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2006-10-18","modifiedBy":"COOPERM","dateModified":"2019-04-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"2962D840-ED56-4EC3-E044-0003BA3F9857","beginDate":"2007-02-13","endDate":null,"createdBy":"ALAIS","dateCreated":"2007-02-13","modifiedBy":"ALAIS","dateModified":"2007-02-13","deletedIndicator":"No"},{"value":"Multiple Myeloma","valueDescription":"Plasma Cell Myeloma","ValueMeaning":{"publicId":"2559811","version":"1","preferredName":"Plasma Cell Myeloma","longName":"2559811","preferredDefinition":"A bone marrow-based plasma cell neoplasm characterized by a serum monoclonal protein and skeletal destruction with osteolytic lesions, pathological fractures, bone pain, hypercalcemia, and anemia.  Clinical variants include non-secretory myeloma, smoldering myeloma, indolent myeloma, and plasma cell leukemia. (WHO, 2001)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Multiple Myeloma","conceptCode":"C3242","definition":"A bone marrow-based plasma cell neoplasm characterized by a serum monoclonal protein and skeletal destruction with osteolytic lesions, pathological fractures, bone pain, hypercalcemia, and anemia.  Clinical variants include non-secretory myeloma, smoldering myeloma, indolent myeloma, and plasma cell leukemia. (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B6B0-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"CURTIST","dateModified":"2011-04-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"2962D840-ED6D-4EC3-E044-0003BA3F9857","beginDate":"2007-02-13","endDate":null,"createdBy":"ALAIS","dateCreated":"2007-02-13","modifiedBy":"ALAIS","dateModified":"2007-02-13","deletedIndicator":"No"},{"value":"Other","valueDescription":"Other","ValueMeaning":{"publicId":"2567790","version":"1","preferredName":"Other","longName":"2567790","preferredDefinition":"Different than the one(s) previously specified or mentioned.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D5DB-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-12-31","endDate":null,"createdBy":"SBREXT","dateCreated":"2003-12-31","modifiedBy":"KUMMEROA","dateModified":"2023-11-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"2962D840-ED79-4EC3-E044-0003BA3F9857","beginDate":"2007-02-13","endDate":null,"createdBy":"ALAIS","dateCreated":"2007-02-13","modifiedBy":"ALAIS","dateModified":"2007-02-13","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2234813","version":"1","preferredName":"Type","preferredDefinition":"Type; a subdivision of a particular kind of thing.","longName":"C25284","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"F970CDF6-F90E-21D3-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-14","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-06-14","modifiedBy":"SBR","dateModified":"2005-09-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2962D75D-EB31-4D5E-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-02-13","endDate":null,"createdBy":"ALAIS","dateCreated":"2007-02-13","modifiedBy":"CURTIST","dateModified":"2011-04-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2857180","version":"1","longName":"Type of Category","context":"NIDCR","ClassificationSchemeItems":[{"publicId":"2812084","version":"1","longName":"Diagnostic","context":"NIDCR"},{"publicId":"2812085","version":"1","longName":"Preventive","context":"NIDCR"}]},{"publicId":"2857182","version":"1","longName":"Protocol Forms","context":"NIDCR","ClassificationSchemeItems":[{"publicId":"2812041","version":"1","longName":"NIDCR","context":"NIDCR"}]}],"AlternateNames":[],"ReferenceDocuments":[{"name":"Have you been treated for any","type":"Preferred Question Text","description":"Have you been treated for any of the following cancers","url":null,"context":"NIDCR"}],"origin":"PEARL CRF:Practitioners Engaged in Applied Research and Learning Network Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"2962DECC-8D90-4FD1-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-02-13","endDate":null,"createdBy":"ALAIS","dateCreated":"2007-02-13","modifiedBy":"ALAIS","dateModified":"2011-08-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}